Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
Neumora Therapeutics (Nasdaq: NMRA), a clinical-stage biopharmaceutical company, has announced it will host a conference call and live webcast to discuss its first quarter 2025 financial results on Monday, May 12, 2025, at 4:30 p.m. ET.
The company, which maintains a pipeline of seven brain disease programs including two clinical-stage programs, will also provide a business update during the call. Interested participants can access the webcast through the events and presentations section of Neumora's website, with a replay available for up to 30 days after the event.
Neumora Therapeutics (Nasdaq: NMRA), un'azienda biofarmaceutica in fase clinica, ha annunciato che terrà una conference call e una diretta web per discutere i risultati finanziari del primo trimestre 2025 lunedì 12 maggio 2025 alle 16:30 ET.
L'azienda, che gestisce un portafoglio di sette programmi per malattie cerebrali, di cui due in fase clinica, fornirà anche un aggiornamento sulle attività durante la chiamata. I partecipanti interessati potranno accedere alla diretta tramite la sezione eventi e presentazioni del sito web di Neumora, con la possibilità di rivedere la registrazione fino a 30 giorni dopo l'evento.
Neumora Therapeutics (Nasdaq: NMRA), una empresa biofarmacéutica en etapa clínica, ha anunciado que realizará una llamada de conferencia y una transmisión en vivo para discutir los resultados financieros del primer trimestre de 2025 el lunes 12 de mayo de 2025 a las 4:30 p.m. ET.
La compañía, que cuenta con una cartera de siete programas para enfermedades cerebrales, incluyendo dos en etapa clínica, también ofrecerá una actualización comercial durante la llamada. Los interesados podrán acceder a la transmisión a través de la sección de eventos y presentaciones en el sitio web de Neumora, con una repetición disponible hasta 30 días después del evento.
Neumora Therapeutics (나스닥: NMRA)는 임상 단계의 바이오제약 회사로서, 2025년 5월 12일 월요일 오후 4시 30분(동부시간)에 2025년 1분기 재무 실적을 논의하기 위한 컨퍼런스 콜 및 라이브 웹캐스트를 개최할 것이라고 발표했습니다.
임상 단계 프로그램 두 개를 포함한 7개의 뇌 질환 프로그램을 보유한 이 회사는 통화 중에 사업 현황 업데이트도 제공할 예정입니다. 관심 있는 참가자는 Neumora 웹사이트의 이벤트 및 프레젠테이션 섹션을 통해 웹캐스트에 접속할 수 있으며, 이벤트 종료 후 최대 30일간 다시보기 서비스를 이용할 수 있습니다.
Neumora Therapeutics (Nasdaq : NMRA), une entreprise biopharmaceutique en phase clinique, a annoncé qu'elle organisera une conférence téléphonique et une diffusion en direct pour discuter des résultats financiers du premier trimestre 2025 le lundi 12 mai 2025 à 16h30 ET.
L'entreprise, qui dispose d'un portefeuille de sept programmes sur les maladies cérébrales, dont deux en phase clinique, fournira également une mise à jour commerciale lors de l'appel. Les participants intéressés pourront accéder à la diffusion via la section événements et présentations du site web de Neumora, avec une rediffusion disponible jusqu'à 30 jours après l'événement.
Neumora Therapeutics (Nasdaq: NMRA), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, hat angekündigt, am Montag, den 12. Mai 2025, um 16:30 Uhr ET eine Telefonkonferenz und eine Live-Webcast abzuhalten, um die Finanzergebnisse des ersten Quartals 2025 zu besprechen.
Das Unternehmen, das über eine Pipeline von sieben Programmen für Hirnerkrankungen verfügt, darunter zwei Programme in der klinischen Phase, wird während des Anrufs auch ein Geschäftsupdate geben. Interessierte Teilnehmer können über den Bereich Veranstaltungen und Präsentationen auf der Website von Neumora auf den Webcast zugreifen, eine Aufzeichnung ist bis zu 30 Tage nach der Veranstaltung verfügbar.
- None.
- None.
WATERTOWN, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including two clinical-stage programs, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Monday, May 12, 2025 to report its first quarter 2025 financial results and provide a business update.
A live webcast of the event will be available on the events and presentations section of the Company’s website at www.neumoratx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call.
About Neumora
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our therapeutic pipeline currently consists of seven neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Our work is supported by an integrated suite of translational, clinical, and computational tools to generate insights that can enable precision medicine approaches. Neumora’s mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases.
Neumora Contact:
Helen Rubinstein
617-402-5700
Helen.Rubinstein@neumoratx.com
FAQ
When will Neumora Therapeutics (NMRA) release Q1 2025 earnings?
How many drug development programs does Neumora Therapeutics (NMRA) currently have?
How can investors access Neumora's (NMRA) Q1 2025 earnings call?
How long will Neumora's (NMRA) Q1 2025 earnings webcast replay be available?
